News

The neurologist from Cleveland Clinic discussed his study presented at AAN 2021 involving the use of responsive neurostimulation in older adults with drug-resistant focal epilepsy and further expanding research in this space.

Researchers found that patients with epilepsy that later died from SUDEP had an abnormal cardiac response after hyperventilation.

Kim Bishop, PhD, and Arnold Gammaitoni, PharmD, discussed the ways fenfluramine impacts not only seizure frequency, but executive function in individuals with Lennox-Gastaut syndrome.

The director at AbbVie highlighted where atogepant stands among the increasing treatment landscape of anti-calcitonin gene-related peptide options within the migraine treatment landscape.

After in-clinic therapy, participants in the Paired VNS group showed a 5.0-point improvement in the Upper Extremity Fugl-Meyer Assessment compared to 2.4 points in controls.

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic spoke to a study using the digital Manual Dexterity Test.

A survey of more than 500 individuals also found that dyskinesia impacted social interactions and reported that OFF time was isolating.

The director of the sleep disorders center at Cleveland Clinic discussed her investigations into low-sodium oxybate presented at AAN 2021.

The professor of neurology at Mayo Clinic discussed the effects social determinants of health can have on epilepsy treatment outcomes and where research needs to turn to next.

Before first diagnosis, patients with multiple sclerosis had more frequent encounters with medical doctors of different specialties compared to matched controls.

Two experts in spinal muscular atrophy (SMA) care, Diana Castro, MD, and Garey H. Noritz, MD, offer tips and demonstrations for screening and diagnosing SMA via telehealth, and they outline resources provided by Cure SMA for families and clinicians who suspect, or have a patient with a diagnosis of, SMA.

The director of research at St. Luke’s Sleep Medicine and Research Center detailed the reasons for residual excessive daytime sleepiness and the lack of literature on the topic.

Here's what is coming soon to NeurologyLive.

The dean at the University of Exeter Medical School discussed ongoing studies of pimavanserin and his thoughts on the FDA’s actions related to the agent.

AbbVie recently announced a new phase 3 study (NCT04380142), called M15-736, which will measure the efficacy, safety, and tolerability of continuous subcutaneous infusion of ABBV-951.

The associate professor of neurology and neurologist at Duke University provided insight on the unique mechanism of nipocalimab and its effect on patients with myasthenia gravis.

Cladribine, which was represented in the highest proportion of patients developing protective SARS-CoV-2 antibody response among other DMTs, had humoral response findings independent of lymphocyte count.

Episode 10 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University and Robert C. Byrd Health; and Albert L. Wright, Jr., the president and CEO of West Virginia University Health System. [WATCH TIME: 4 minutes]

The chief scientific officer of the Parkinson’s Foundation and adjunct associate professor in the Department of Neuroscience and Physiology at New York University School of Medicine discussed the adoption of telemedicine in Parkinson disease care.

Neurology News Network for the week ending May 1, 2021.

The World Sleep Society Narcolepsy Task Force surveyed clinicians in an effort to understand regional differences in the diagnosis and management of narcolepsy.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 30, 2021.

The director of research at St. Luke’s Sleep Medicine and Research Center discussed the motivation behind her study assessing solriamfetol in patient’s adherent and nonadherent to primary OSA therapy.

NMOSD is associated with elevated levels of the pleiotropic cytokine interleukin-6, making the cytokine an apt therapeutic target.

The Vice-Chair for Research at the Cleveland Clinic Neurological Institute discussed topline results from the EMPhASIS trial of IMU-838.

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD.

Just weeks after receiving an EU marketing authorization, the FDA has issued a complete response letter to Biogen for its sBLA related to the subcutaneous administration of natalizumab (Tysabri).

A trio of clinicians from Georgetown University explore the current status of disease-modifying therapies for individuals with Parkinson disease.

Apic Bio plans to initiate a phase 1/2 clinical trial in late 2021 or early 2022 as a multi-center, 3-part study to evaluate APB-102 in patients with SOD1-ALS mutations.

The director of the Center for Neurological Restoration at Cleveland Clinic provided an inside perspective on how the MANAGE-PD tool can effectively assist in the Parkinson disease screening process.